Posted by Michael Wonder on 16 Aug 2021
Edgewise receives U.S. FDA fast track designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy
16 August 2021 - EDG-5506, a drug candidate designed to arrest muscle fibre breakdown in Becker and Duchenne muscular dystrophy, continues to advance in Phase 1.
Edgewise Therapeutics today announced that the U.S. FDA has granted fast track designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy.
